Efficacy and tolerability of ixazomib, daratumumab and low dose dexamethasone (IDd) followed by ixazomib and daratumumab maintenance therapy until progression for a maximum of 2 years in unfit and frail newly diagnosed multiple myeloma patients; an open-label phase II trial
Latest Information Update: 20 Sep 2024
Price :
$35 *
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab (Primary) ; Ixazomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms HOVON 143 MM
- 20 Sep 2024 This trial has been completed in Belgium (Global end date: 2024-05-02) according to European Clinical Trials Database record.
- 12 Dec 2023 Results analyzing cell subsets related to frailty status, their predictive value for treatment outcome, and their dynamics during treatment, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in this study presented at the 65th American Society of Hematology Annual Meeting and Exposition